Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
From Novice to Master: Dominating a Side interest- Damaged Shenzhou-20 spacecraft to return to Earth uncrewed for inspection
- The Best Portable Applications for Psychological wellness and Prosperity
- Best Streaming Gadget for Your Home Theater
- Corcept Therapeutics shares surge as lead drug gets FDA nod for ovarian cancer
- AfD faction in western Germany ousts councilman for firebrand speech
- From invasive species tracking to water security – what’s lost with federal funding cuts at US Climate Adaptation Science Centers
- Doctors thought he had cancer. An offhand suggestion led to a rare diagnosis.
- Lily Allen 2026 'West End Girl' arena tour: How to get tickets, prices and more
